BioPharma Resources

Drug Trial Radar · NCT05955326

Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

A Prospective, Multicentric, Randomized, Double-blind, Parallel, Phase IV Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Jan 8, 2024

Primary completion

Dec 18, 2026

Study completion Dec 18, 2026

Sponsor

Lead sponsor
Pharmazz, Inc.Industry
Sponsor type
Industry
First posted
Jul 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 78 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multicenter, randomized, double-blind, parallel, phase IV study designed to evaluate the safety and efficacy of sovateltide (PMZ-1620, IRL-1620) as a potential treatment for cerebral ischemic stroke.

Conditions

  • Acute Cerebral Ischemia

Interventions

  • SovateltideDrug

    Sovateltide (Tyvalzi™) is a highly selective ETB receptor agonist (Ki values are 0.016 and 1900 nM at ETB and ETA receptors, respectively). It is being developed as a first-in-class neuronal progenitor cell therapy for acute cerebral ischemic stroke. Sovateltide has demonstrated a significant neuroprotection following cerebral ischemia in animal models, while in a clinical phase I trial it was found safe and well-tolerated in healthy human volunteers (CTRI/2016/11/007509). A phase II study (NCT04046484) in 40 patients with cerebral ischemic stroke has demonstrated its superior efficacy with a significant improvement compared to the standard of care and widens the critical time window from 4 hours to 24 hours. A phase III study (NCT04047563) has also been recently completed in 158 patients with cerebral ischemic stroke, demonstrating significant improvement compared to the standard of care.

  • Normal SalineOther

    Three doses of Normal Saline (0.9% NaCl solution) with a volume equal to the volume of sovateltide will be administered as an IV bolus over one minute, at an interval of 3 hours ± 1 hour on day 1. The dose will be repeated on day 3 and day 6 post-randomization. All the patients in the Normal Saline group will continue receiving standard treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients with adverse events (AEs) and serious adverse events (SAEs)Time frame: 90 days

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Guntur Medical College and Government General Hospital

    Guntur, Andhra Pradesh, India

  • Lalitha Super Specialities Hospital Pvt. Ltd.

    Guntur, Andhra Pradesh, India

  • Radiant Superspeciality Hospital

    Amravati, Maharashtra, India

  • Government Medical College and attached Hospitals

    Kota, Rajasthan, India

  • KG Hospital and Post Graduate Medical Institute

    Coimbatore, Tamil Nadu, India

  • Maharani Laxmibai Medical College

    Jhānsi, Uttar Pradesh, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.